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Objective. To present the case of a patient with brain metastases from breast cancer treated with Lapatinib and radiotherapy, who
developed an unexpected neurological disorder, and literature review.
Materials and methods. A 68-year old woman treated with neoadjuvant chemotherapy, mastectomy and adjuvant radiotherapy
for inﬁltrating lobular carcinoma pT2N2M0. After a two years of disease free interval, she developed bitemporal homonymous
hemianopsia, andwasdiagnosed byMRI ofmultiplemetastases in the brain, one localized in sellar regionwith compression of the
optic chiasm, two in the brain stemand three in both cerebellar hemispheres. The patient receivedwith 3Dholocraneal EBRTwith
a total dose of 35Gy 2.5Gy/day. After ﬁnishing treatment she showed improvement of visual symptoms. Subsequently, the patient
began treatment with Lapatinib (1250mg/day), requiring hospitalization in two occasions due to diarrhea and vomiting. Two
months later a brain MRI was performed, showing an 80% reduction in tumor volume of the sellar lesion, as well as others lesions.
Three months later of undergoing therapy with Lapatinib, she showed extrapyramidal clinical cognitive deﬁcits associated with
conduct disorder, and was diagnosed with atypical Parkinsonism after ruling out paraneoplastic origin.
Discussion and conclusion. The patient showed a signiﬁcant improvement in visual symptoms and a reduction in tumor volume
greater than 50% after treatment with Lapatinib and Radiotherapy; however she developed an extrapyramidal syndrome (ES)
later. At present, there is no data in the literature describing an ES neither after holocraneal radiotherapy nor as a side effect
of Lapatinib. The combination of both treatments in this patient during the same period of time made it possible to set down
ES as a result of interaction between both therapies, taking into account Lapatinib’s ability to cross the blood–brain barrier. The
neurological disorder progressed rapidly, resulting in the death of the patient, without evidence of tumor progression.
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Objectives. The purpose of this study was to analyse different approaches to correctly assess PTV doses in breast forward IMRT
(FIMRT).
Materials and methods. We selected a group of 40 patients undergoing radiotherapy after breast conserving surgery. Target volumes
were outlined: breast CTV and, by expansion, a PTV that extends outside the body surface. Two sub-volumes of PTV were further
established: a PTV-SV1, corresponding to the PTV 3 mm inside the body, and a PTV-SV2, corresponding to the rest of the PTV
(mostly air). For each patient 3 dosimetric planswere calculated according to the following situations: Plan 1. Using the delineated
PTV extended outside the body surface. Plan 2. Extending the body surface to include all PTV volume. Plan 3. Same as Plan 2 but
attributing a density to PTV-SV2 equal to the mean breast density. For each of these situations we evaluated the mean dose to
PTV and PTV-SV1 according to the ICRU 83 Report.
Results. We obtained different results for each of the studied situations. In all approaches the Dmean to PTV-SV1 was similar to
the prescription dose of 50Gy. However, only when a density was attributed to PTV-SV2 (Plan 3) the Dmean in PTV approached
the prescription dose.
Conclusions. According to ICRU 83 report, to correctly evaluate PTV volumes extended outside the body surface, several methods
have been proposed, for example by extending the beam intensity values from the breast periphery to the regions outside the
body. By attributing a density value to PTV-SV2 we were able to achieve this same goal even without the recurring to special IMRT
tools, not always available.
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